Temozolomide (NSC 362856), DNA Alkylator

Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects. - Mechanism of Action & Protocol.

Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations

Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas, BMC Cancer

Novel Imidazotetrazine Evades Known Resistance Mechanisms and Is Effective against Temozolomide-Resistant Brain Cancer in Cell Culture

Bioequivalence study of 20-mg and 100-mg temozolomide capsules (TOZ309 and Temodal®) in glioma patients in China

Novel strategies of Raman imaging for monitoring the therapeutic benefit of temozolomide in glioblastoma - ScienceDirect

Temozolomide 85622-93-1 wiki

Temozolomide function and activated DNA repair pathway. Temozolomide

PDF) Phase I study of temozolomide in paediatric patients with advanced cancer

Biomedicines, Free Full-Text

Tunable Stability of Imidazotetrazines Leads to a Potent Compound for Glioblastoma